Jeneng Obat Orphan Anyar kanggo Perawatan Limfoma Folikular

Januari 21, 2022
by editor
Tambah Komentar
2 min maca
en English
af Afrikaanssq Albanianam Amharicar Arabichy Armenianaz Azerbaijanieu Basquebe Belarusianbn Bengalibs Bosnianbg Bulgarianca Catalanceb Cebuanony Chichewazh-CN Chinese (Simplified)zh-TW Chinese (Traditional)co Corsicanhr Croatiancs Czechda Danishnl Dutchen Englisheo Esperantoet Estoniantl Filipinofi Finnishfr Frenchfy Frisiangl Galicianka Georgiande Germanel Greekgu Gujaratiht Haitian Creoleha Hausahaw Hawaiianiw Hebrewhi Hindihmn Hmonghu Hungarianis Icelandicig Igboid Indonesianga Irishit Italianja Japanesejw Javanesekn Kannadakk Kazakhkm Khmerko Koreanku Kurdish (Kurmanji)ky Kyrgyzlo Laola Latinlv Latvianlt Lithuanianlb Luxembourgishmk Macedonianmg Malagasyms Malayml Malayalammt Maltesemi Maorimr Marathimn Mongolianmy Myanmar (Burmese)ne Nepalino Norwegianps Pashtofa Persianpl Polishpt Portuguesepa Punjabiro Romanianru Russiansm Samoangd Scottish Gaelicsr Serbianst Sesothosn Shonasd Sindhisi Sinhalask Slovaksl Slovenianso Somalies Spanishsu Sudanesesw Swahilisv Swedishtg Tajikta Tamilte Teluguth Thaitr Turkishuk Ukrainianur Urduuz Uzbekvi Vietnamesecy Welshxh Xhosayi Yiddishyo Yorubazu Zulu
ditulis dening editor

CASI Pharmaceuticals, Inc., perusahaan biofarmasi AS sing fokus ing ngembangake lan komersialisasi produk terapeutik lan farmasi sing inovatif, ngumumake dina iki, yen US Food and Drug Administration (FDA) wis menehi Orphan Drug Designation (ODD) menyang partner BioInvent International AB, kanggo BI-1206, antibodi anti-FcyRllB sing diselidiki, kanggo perawatan limfoma folikel (FL), wangun paling umum saka limfoma Non-Hodgkin (NHL) sing tuwuh alon-alon.

Print Friendly, PDF & Email

BI-1206 minangka calon obat utama BioInvent lan saiki diselidiki ing rong uji coba Fase 1/2. Salah sijine ngevaluasi kombinasi BI-1206 karo rituximab kanggo perawatan limfoma Non-Hodgkin, sing kalebu pasien FL, MCL lan limfoma zona marginal (MZL) sing wis kambuh utawa refrakter kanggo rituximab. Uji coba Fase 1/2 kapindho nyelidiki BI-1206 kanthi kombinasi karo terapi anti-PD1 Keytruda® (pembrolizumab) ing tumor padhet.

Dr. Wei-Wu He, Ketua, lan CEO CASI menehi komentar, "BioInvent terus maju kanthi pangembangan lan kerangka regulasi kanggo BI-1206. Persetujuan CTA ing China ing Desember 2021 lan FDA Orphan Drug Designation anyar nuduhake potensial kuat antibodi kelas pertama iki. CASI duwe hak komersial China BI-1026, lan tim kita lagi nyiapake kanggo sinau klinis China. CASI lan BioInvent minangka mitra sing lancar lan duwe tujuan umum kanggo entuk manfaat kanggo pasien kanthi teknologi farmasi sing inovatif.

Print Friendly, PDF & Email
Liyane babagan: |

Berita sing gegandhengan

Sampeyan uga kaya

About penulis

editor

Pemimpin editor kanggo eTurboNew yaiku Linda Hohnholz. Dheweke adhedhasar ing HQ eTN ing Honolulu, Hawaii.

Ndeleng kabeh postingan

Ninggalake Komentar